• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • Settings
  • RSS Feeds
PublishDashboard
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI employees
    Legal
    Terms of usePrivacy policyCookie policy

    SEC Form DEFA14A filed by Supernus Pharmaceuticals Inc.

    4/30/25 4:19:32 PM ET
    $SUPN
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $SUPN alert in real time by email
    DEFA14A 1 tm252405d3_defa14a.htm DEFA14A

     

     

    UNITED STATES

    SECURITIES AND EXCHANGE COMMISSION

    Washington, D.C. 20549

     

    SCHEDULE 14A

     

    PROXY STATEMENT PURSUANT TO SECTION 14(a) OF THE

    SECURITIES EXCHANGE ACT OF 1934

     

    FILED BY THE REGISTRANT x

     

    FILED BY A PARTY OTHER THAN THE REGISTRANT ¨

     

    Check the appropriate box:

     

    ¨Preliminary Proxy Statement

     

    ¨Confidential, for Use of the Commission Only (as permitted by Rule 14a-6(e)(2))

     

    ¨Definitive Proxy Statement

     

    xDefinitive Additional Materials

     

    ¨Soliciting Material under §240.14a-12

     

    SUPERNUS PHARMACEUTICALS, INC.

     

    (Name of the Registrant as Specified In Its Charter)

     

     

    (Name of Person(s) Filing Proxy Statement, if other than the Registrant)

     

    Payment of Filing Fee (Check the appropriate box):

     

    xNo fee required.

     

    ¨Fee paid previously with preliminary materials.

     

    ¨Fee computed on table in exhibit required by Item 25(b) per Exchange Act Rules 14a6(i)(1) and 0-11.

     

     

     

     

    GRAPHIC

    www.edocumentview.com/SUPN Step 1: Go to www.investorvote.com/SUPN. Step 2: Click on the icon on the right to view meeting materials. Step 3: Return to the investorvote.com window and follow the instructions on the screen to log in. Online Go to www.investorvote.com/SUPN or scan the QR code — login details are located in the shaded bar below. Stockholder Meeting Notice 045DAA Important Notice Regarding the Availability of Proxy Materials for the Supernus Pharmaceuticals, Inc. Stockholder Meeting to be Held on June 16, 2025 Under Securities and Exchange Commission rules, you are receiving this notice that the proxy materials for the annual stockholders’ meeting are available on the Internet. Follow the instructions below to view the materials and vote online or request a copy. The items to be voted on and location of the annual meeting are on the reverse side. Your vote is important! This communication presents only an overview of the more complete proxy materials that are available to you on the Internet. We encourage you to access and review all of the important information contained in the proxy materials before voting. The Notice of Annual Meeting of Stockholders, Proxy Statement and 2024 Annual Report are available on the Internet at: Obtaining a Copy of the Proxy Materials – If you want to receive a copy of the proxy materials, you must request one. There is no charge to you for requesting a copy. Please make your request as instructed on the reverse side on or before June 6, 2025 to facilitate timely delivery. 2NOT Easy Online Access — View your proxy materials and vote. When you go online, you can also help the environment by consenting to receive electronic delivery of future materials. Supernus Pharmaceuticals, Inc. Step 4: Make your selections as instructed on each screen for your delivery preferences. Step 5: Vote your shares.

    GRAPHIC

    Here’s how to order a copy of the proxy materials and select delivery preferences: Current and future delivery requests can be submitted using the options below. If you request an email copy, you will receive an email with a link to the current meeting materials. PLEASE NOTE: You must use the number in the shaded bar on the reverse side when requesting a copy of the proxy materials. — Internet – Go to www.investorvote.com/SUPN. — Phone – Call us free of charge at 1-866-641-4276. — Email – Send an email to [email protected] with “Proxy Materials Supernus Pharmaceuticals, Inc.” in the subject line. Include your full name and address, plus the number located in the shaded bar on the reverse side, and state that you want a paper copy of the meeting materials. To facilitate timely delivery, requests for a paper copy of proxy materials must be received by June 6, 2025. The 2025 Annual Meeting of Stockholders of Supernus Pharmaceuticals, Inc. will be held on June 16, 2025 at 10:00 A.M. Eastern Daylight Time, virtually via the Internet at meetnow.global/MXGLRPM. To access the virtual meeting, you must have the information that is printed in the shaded bar located on the reverse side of this form. Proposals to be voted on at the meeting are listed below along with the Board of Directors’ recommendations. The Board of Directors recommend a vote FOR all the nominees listed, FOR Proposals 2 and 3, and AGAINST Proposal 4: 1. to elect two (2) directors to hold office for the ensuing three years and until their successors have been duly elected and qualified: 01 - Carrolee Barlow, M.D., Ph.D 02 - Jack A. Khattar 2. to approve, on a non-binding basis, the compensation paid to our named executive officers; 3. to ratify the appointment of KPMG LLP as our independent registered public accounting firm for the fiscal year ending December 31, 2025; 4. to consider and vote upon a stockholder proposal, if included in our Proxy Statement for the Annual Meeting of Stockholders (the “Proxy Statement”) and properly presented at the meeting; and 5. to transact such other business as may properly come before the Annual Meeting or any adjournment or adjournments thereof. PLEASE NOTE – YOU CANNOT VOTE BY RETURNING THIS NOTICE. To vote your shares you must go online or request a paper copy of the proxy materials to receive a proxy card. Stockholder Meeting Notice

    Get the next $SUPN alert in real time by email

    Chat with this insight

    Save time and jump to the most important pieces.

    Recent Analyst Ratings for
    $SUPN

    DatePrice TargetRatingAnalyst
    2/19/2025$57.00 → $36.00Overweight → Neutral
    Cantor Fitzgerald
    1/6/2025$57.00Overweight
    Cantor Fitzgerald
    9/11/2024$41.00 → $36.00Overweight → Neutral
    Piper Sandler
    1/3/2023$44.00 → $45.00Buy
    Jefferies
    12/1/2021$40.00 → $44.00Buy
    Jefferies
    More analyst ratings

    $SUPN
    Leadership Updates

    Live Leadership Updates

    See more
    • Jay Glazer Teams Up with Supernus Pharmaceuticals to Raise Awareness of ADHD and his Qelbree® Journey

      Jay is sharing his story of receiving an ADHD diagnosis and eventually finding his treatment approach with Qelbree15.7 million U.S. children, teens and adults estimated to have been diagnosed with ADHD1,2 ROCKVILLE, Md., Oct. 16, 2023 (GLOBE NEWSWIRE) -- Television personality and sports reporter Jay Glazer is opening up about his personal experiences with attention-deficit/hyperactivity disorder (ADHD) – one of the most common psychiatric diagnoses affecting approximately 10 million adults in the U.S. – and with Qelbree (viloxazine extended-release capsules), a nonstimulant medication for the treatment of ADHD.3 Glazer, who has always been outspoken about his mental health struggles, wa

      10/16/23 5:34:21 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    See more
    • Supernus Pharma downgraded by Cantor Fitzgerald with a new price target

      Cantor Fitzgerald downgraded Supernus Pharma from Overweight to Neutral and set a new price target of $36.00 from $57.00 previously

      2/19/25 7:05:55 AM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Cantor Fitzgerald initiated coverage on Supernus Pharma with a new price target

      Cantor Fitzgerald initiated coverage of Supernus Pharma with a rating of Overweight and set a new price target of $57.00

      1/6/25 8:47:11 AM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus Pharma downgraded by Piper Sandler with a new price target

      Piper Sandler downgraded Supernus Pharma from Overweight to Neutral and set a new price target of $36.00 from $41.00 previously

      9/11/24 7:45:40 AM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    SEC Filings

    See more
    • Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Submission of Matters to a Vote of Security Holders, Financial Statements and Exhibits

      8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

      6/17/25 4:40:35 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Entry into a Material Definitive Agreement, Other Events, Financial Statements and Exhibits

      8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

      6/16/25 8:34:38 AM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus Pharmaceuticals Inc. filed SEC Form 8-K: Other Events, Financial Statements and Exhibits

      8-K - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Filer)

      5/28/25 4:09:14 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    Insider Trading

    Insider transactions reveal critical sentiment about the company from key stakeholders. See them live in this feed.

    See more
    • President, CEO Khattar Jack A. acquired 16,850 shares and disposed of 16,850 shares, increasing direct ownership by 2% to 1,008,683 units (SEC Form 4)

      4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

      4/3/25 4:27:28 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • President, CEO Khattar Jack A. converted options into 35,000 shares and covered exercise/tax liability with 16,805 shares, increasing direct ownership by 2% to 991,833 units (SEC Form 4)

      4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

      3/11/25 4:17:35 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Senior Vice-President & CFO Dec Timothy C converted options into 3,800 shares and covered exercise/tax liability with 2,017 shares, increasing direct ownership by 16% to 12,681 units (SEC Form 4)

      4 - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Issuer)

      3/11/25 4:15:41 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    Press Releases

    Fastest customizable press release news feed in the world

    See more
    • Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

      Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform.Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 million or $12.00 per share.Supernus to host confe

      6/16/25 7:00:06 AM ET
      $SAGE
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Jay Glazer and Wife Rosie Glazer Offer Candid Look at ADHD and Relationships in New Qelbree® Content Series with Supernus Pharmaceuticals

      ROCKVILLE, Md., May 29, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals is expanding its partnership with TV personality and sports reporter Jay Glazer in a new content series featuring his wife, Rosie Glazer. The series, which launches its first episode on the All About ADHD YouTube channel in May for Mental Health Awareness Month, offers an intimate look at how ADHD impacts relationships and how Qelbree (viloxazine extended-release capsules), a non-stimulant ADHD treatment for people 6 years and older, has played a role in Jay's ADHD treatment journey.  The four-part video series delves into Jay's experience with ADHD through the lens of his relationship with Rosie, offering unique pe

      5/29/25 8:30:51 AM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus Announces Paragraph IV ANDA Filings for Qelbree®

      ROCKVILLE, Md., May 28, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company received Paragraph IV Notice Letters from third parties notifying Supernus that the third parties submitted Abbreviated New Drug Applications (ANDAs) for viloxazine extended-release capsules, eq. 100, 150, and 200 mg base. Supernus is currently reviewing the details of these Notice Letters and intends to vigorously enforce its intellectual property rights relating to Qelbree. The U.S. Food and Drug Administration's Orange Book

      5/28/25 4:05:32 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    Financials

    Live finance-specific insights

    See more
    • Supernus Pharmaceuticals to Acquire Sage Therapeutics, Strengthening its Neuropsychiatry Product Portfolio

      Proposed acquisition expected to accelerate mid- to long-term revenue and cash flow growth and further diversify revenue base.Strengthens Supernus' leading presence in neuropsychiatric conditions with an innovative commercial product, ZURZUVAE® (zuranolone), and a novel CNS discovery platform.Expected to be significantly accretive in 2026 with potential cost synergies of up to $200 million on an annual basis.Upfront cash payment of $8.50 per share, plus one non-tradable contingent value right (CVR) payable upon achieving certain specific milestones collectively worth up to $3.50 per share in cash, for an aggregate of up to approximately $795 million or $12.00 per share.Supernus to host confe

      6/16/25 7:00:06 AM ET
      $SAGE
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus Announces First Quarter 2025 Financial Results

      First quarter 2025 net sales of Qelbree® increased 44% to $64.7 million, compared to the same period in 2024.First quarter 2025 net sales of GOCOVRI® increased 16% to $30.7 million, compared to the same period in 2024.First quarter 2025 total revenues increased 4% to $149.8 million, compared to the same period in 2024. First quarter 2025 total revenues excluding Trokendi XR® and Oxtellar XR® net sales (non-GAAP)(1) increased 26% compared to the first quarter of 2024.First quarter 2025 operating loss of $(10.3) million, compared to operating loss of $(3.2) million in 2024. First quarter adjusted operating earnings (non-GAAP)(1) increased 16% to $25.9 million.ONAPGO™ (apomorphine hydrochloride

      5/6/25 4:08:06 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Supernus Pharmaceuticals to Announce First Quarter 2025 Financial Results and Host Conference Call and Webcast on May 6, 2025

      ROCKVILLE, Md., April 23, 2025 (GLOBE NEWSWIRE) -- Supernus Pharmaceuticals, Inc. (NASDAQ:SUPN), a biopharmaceutical company focused on developing and commercializing products for the treatment of central nervous system (CNS) diseases, today announced that the Company expects to report financial and business results for the first quarter of 2025 after the market closes on Tuesday, May 6, 2025. Jack Khattar, President and CEO, and Tim Dec, Senior Vice President and CFO, will host a conference call to present the first quarter 2025 financial and business results on Tuesday, May 6, 2025 at 4:30 p.m. ET. Following management's prepared remarks and discussion of business results, the call will

      4/23/25 5:14:00 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care

    $SUPN
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    See more
    • Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

      SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

      11/14/24 5:14:42 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • Amendment: SEC Form SC 13G/A filed by Supernus Pharmaceuticals Inc.

      SC 13G/A - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

      11/1/24 4:35:56 PM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care
    • SEC Form SC 13G filed by Supernus Pharmaceuticals Inc.

      SC 13G - SUPERNUS PHARMACEUTICALS, INC. (0001356576) (Subject)

      10/31/24 11:55:00 AM ET
      $SUPN
      Biotechnology: Pharmaceutical Preparations
      Health Care